SAN.NEO Sanofi CDR (CAD Hedged)
- Market cap
- CAD 11.7B
- P/E
- 1.9x
- P/B
- 0.11x
- ROE
- 5.7%
- Dividend yield
- 5.54%
- Fundamental score
- 2.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SAN.NEO undervalued?
Graham numberThe Graham number of Sanofi CDR (CAD Hedged) cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sanofi CDR (CAD Hedged) fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (5.7%), below 10%.
ROA 0/1
Return on assets (3.0%) is below the industry median (7.4%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (45.9%) is below the industry median (90.5%).
Revenue Growth 1/2
Revenue grew 4.8% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (21.2%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 7.1x against interest expense, well covered.
PE vs Market 1/1
PE (1.9x) is below the market median (20.3x).
PE vs Industry 1/1
PE (1.9x) is below the industry median (25.0x).
PBV 1/1
Price to book (0.1x) is below the industry median (8.1x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 0.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (32.7%) is in the top 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 61.1%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Sanofi CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sanofi CDR (CAD Hedged)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a coll…
Full company profileSanofi CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sanofi CDR (CAD Hedged) annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 40.6B | 41.6B | 44.3B | 46.7B | 47.1B |
| Gross Profit | 28.7B | 29.0B | 31.1B | 33.7B | 34.8B |
| Operating Income | 10.9B | 8.69B | 8.92B | 9.60B | 9.31B |
| EBITDA | 13.5B | 11.3B | 11.0B | 12.5B | 8.78B |
| Net Income | 8.37B | 5.40B | 5.56B | 7.81B | 3.91B |
| EPS | 6.64 | 4.32 | 4.44 | 6.47 | 3.27 |
| Balance Sheet | |||||
| Total Assets | 127B | 126B | 133B | 127B | 129B |
| Total Liabilities | 51.6B | 52.1B | 54.9B | 55.1B | 59.5B |
| Shareholders' Equity | 74.8B | 74.0B | 77.5B | 71.4B | 69.2B |
| Cash & Short-term Investments | 12.7B | 8.71B | 7.44B | 7.66B | 6.35B |
| Cash Flow | |||||
| Operating Cash Flow | 10.5B | 10.3B | 9.08B | 10.8B | 9.29B |
| Capital Expenditure | 2.10B | 2.91B | 3.20B | 3.54B | 0.00 |
| Free Cash Flow | 8.42B | 7.35B | 5.89B | 7.21B | 6.69B |
| Ratios | |||||
| ROE | 11.2% | 7.3% | 7.2% | 10.9% | 5.7% |
| ROA | 6.6% | 4.3% | 4.2% | 6.2% | 3.0% |
| Net Profit Margin | 20.6% | 13.0% | 12.6% | 16.7% | 8.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sanofi CDR (CAD Hedged) dividends
- Dividend yield
- 5.54%
- Forward dividend
- 0.53 CAD
- Payout ratio
- 61.1%
- Ex-dividend date
- May 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 4.77B | 3.95 | 61.1% |
| 2024 | EUR 4.70B | 3.75 | 84.6% |
| 2023 | EUR 4.45B | 3.56 | 82.5% |
| 2022 | EUR 4.17B | 3.31 | 49.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sanofi CDR (CAD Hedged)
Ownership data of Sanofi CDR (CAD Hedged) is not available yet.
Sanofi CDR (CAD Hedged) company profile
- Company name
- Sanofi CDR (CAD Hedged)
- Ticker
- SAN.NEO
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 74,846
- Fiscal year end
- December
- Address
- 46, avenue de la Grande ArmEe, Paris, France, 75017
- Phone
- 33 1 53 77 40 00
- Website
- sanofi.com
About Sanofi CDR (CAD Hedged)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. manufacturing facility in Germany. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi CDR (CAD Hedged) management
10- Ms. Belen Garijo Lopez M.D.CEO & Director · born 1960
- Mr. François-Xavier RogerExecutive VP & CFO · born 1962
- Dr. Michael Quigley Ph.D.Chief Scientific Officer & Head of Research
- Mr. Thomas Kudsk LarsenHead of Investor Relations & General Medicines · born 1974
- Ms. Jamie HaneyExecutive VP & General Counsel
- Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global Marketing · born 1957
- Ms. Veronique JailletExecutive VP & Interim Chief People Officer
- Fabrizio GaudiHead of Austrian, German & Swiss Operations
- Mr. Erik WallströmHead of Therapeutic Area - Neurology Development
- Mr. Thomas TriompheExecutive Vice President of Vaccines · born 1974